Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Treprostinil
Drug ID BADD_D02268
Description Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.
Indications and Usage For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Marketing Status approved; investigational
ATC Code B01AC21
DrugBank ID DB00374
KEGG ID D06213
MeSH ID C427248
PubChem ID 6918140
TTD Drug ID D01WUA
NDC Product Code 0703-0696; 0781-3430; 11014-0094; 66302-350; 66302-648; 66302-748; 66302-361; 66302-363; 66302-620; 66302-720; 0703-0676; 43598-646; 43598-647; 66302-302; 66302-325; 66302-616; 66302-362; 0703-0666; 14501-0015; 42023-209; 62332-515; 66302-110; 66302-300; 66302-610; 54893-0024; 43598-649; 62332-514; 62332-517; 66302-102; 66302-206; 66302-732; 58159-041; 68245-0008; 43598-648; 66302-120; 66302-600; 66302-650; 66302-764; 0703-0686; 0781-3420; 0781-3425; 81861-0029; 66302-101; 66302-310; 66302-630; 66302-664; 0781-3427; 42023-206; 66302-105; 66302-640; 42023-207; 62332-516; 66302-632; 66302-716; 42023-208
UNII RUM6K67ESG
Synonyms treprostinil | ((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate | treprostinil sodium | trepostinil sodium | Orenitram | UT-15 | UT-15C | Remodulin | treprostinil diolamine | treprostinil diolamin | treprostinil diethanolamine
Chemical Information
Molecular Formula C23H34O5
CAS Registry Number 81846-19-7
SMILES CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dehydration14.05.05.0010.002040%
Dental caries07.09.01.0010.000419%
Depression19.15.01.001--
Dermatitis23.03.04.0020.000263%Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.0030.007254%Not Available
Diabetic neuropathy17.09.04.002; 14.07.04.003; 05.07.04.0030.000082%Not Available
Diarrhoea07.02.01.0010.040629%
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.000469%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.027355%
Dizziness exertional02.11.04.007; 17.02.05.034; 24.06.02.0180.000502%Not Available
Dizziness postural17.02.05.004; 02.11.04.008; 24.06.02.0080.002443%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry throat22.12.03.005; 07.06.01.0050.000362%Not Available
Dyspepsia07.01.02.0010.002328%
Dysphonia17.02.08.004; 22.12.03.006; 19.19.03.0020.001505%
Dyspnoea02.11.05.003; 22.02.01.0040.059101%
Dyspnoea at rest02.11.05.004; 22.02.01.0250.001127%Not Available
Dyspnoea exertional02.11.05.005; 22.02.01.0050.009540%Not Available
Ear pain04.03.01.0030.000321%
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Electrolyte imbalance14.05.01.0020.000288%Not Available
Emphysema22.01.02.0020.000164%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.003931%
Eructation07.01.02.0030.000419%
Erythema23.03.06.001--Not Available
Eye swelling06.08.03.0030.000880%Not Available
Facial pain08.01.08.0120.000280%
Faeces discoloured07.01.03.0020.000543%Not Available
Failure to thrive19.07.05.001; 18.04.01.003; 14.03.02.0080.000123%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene